Serum tumor biomarker, carcinoembryonic antigen (CEA) and carbohydrate antigen 19–9 (CA19-9) have been used to diagnose PCa and monitor recurrence after surgery, but their accuracy and detection limits are low [4–5]. The gene discussed is CEACAM5; the disease is posterior cortical atrophy.